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Sir,
We were delighted to learn that our article ‘Expression of
carbonic anhydrase IX suggests poor outcome in rectal cancer’
(Korkeila et al, 2009) had been read with great interest.
Span et al (2009) pointed out that the results presented in our
study only allow the statement that ‘Expression of carbonic
anhydrase IX suggests poor response to therapy in rectal cancer’,
which we agree upon.
In our study, there were two index patient groups: (i) 75 patients
who had received preoperative short-course radiotherapy and (ii)
37 patients who had received long-course radiotherapy with or
without chemotherapy. The third group included 54 control
patients, none of whom had received any preoperative treatment.
In this group there were 34 patients who had not received any
postoperative adjuvant treatment (chemotherapy or chemora-
diotherapy) either. To test the effect of adjuvant treatment, we
compared these 34 patients with all the other patients (n¼132).
There was no statistically significant difference (P¼0.604) in
disease-free survival, and the same was true with disease-specific
survival (P¼0.111) in Kaplan–Meier analysis.
To explore this issue further, we also analysed these 54 control
group patients separately, i.e., 20 patients who had received and 34
who had not received any adjuvant chemotherapy. Among those
34 patients who had not received adjuvant therapy, 17 tumours
were CA IX-positive and 17 CA IX-negative. Among those 20 who
had been treated with adjuvant therapy, 11 tumours were CA IX-
positive and 9 were CA IX-negative (P¼0.722). Among the control
group patients who had not received adjuvant therapy, 35% of the
tumours had moderate or strong and 15% weak intensity in CA IX
staining. Among the patients who had been treated with adjuvant
therapy, seven tumours had weak and four tumours had moderate
or strong staining intensity (P¼0.225). There were no statistically
significant differences in DFS or DSS between the patients who had
or had not received adjuvant therapy.
However, a direct comparison between the groups might be
biased by the fact that the patients who had received preoperative
therapy had more advanced tumours. According to our practice,
adjuvant therapy is given whenever indicated due to a high
recurrence risk (node-positive tumours, perforated tumours or
tumours that have caused bowel obstruction, tumours with nerve
or vessel invasion). All these patients who had received adjuvant
therapy had tumours with a higher risk of recurrence.
In conclusion, we agree that ‘Expression of carbonic anhydrase
IX suggests poor response to therapy in rectal cancer’.
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